Therapeutically targeting RNA viruses via lethal mutagenesis

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  De Clercq E: Antiviral drugs in current clinical use. J. Clin. Virol.30(2),115–133 (2004).
  Medline CASGoogle Scholar
• 2  Sidwell RW, Huffman JH, Khare GP et al.: Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science177(50),705–706 (1972).
  Medline CASGoogle Scholar
• 3  Vignuzzi M, Wendt E, Andino R: Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med.14(2),154–161 (2008).▪ Describes the generation of attenuated vaccine virus strains through increasing replication fidelity and restricting viral quasispecies.
  Medline CASGoogle Scholar
• 4  Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R: Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature439(7074),344–348 (2006).▪▪ Small changes in virus fidelity can severely impact viral pathogenesis and tropism.
  Medline CASGoogle Scholar
• 5  Domingo E, Escarmis C, Sevilla N et al.: Basic concepts in RNA virus evolution. FASEB J.10(8),859–864 (1996).
  Medline CASGoogle Scholar
• 6  Drake JW, Holland JJ: Mutation rates among RNA viruses. Proc. Natl Acad. Sci. USA96(24),13910–13913 (1999).
  Medline CASGoogle Scholar
• 7  Steinhauer DA, Domingo E, Holland JJ: Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene122(2),281–288 (1992).
  Medline CASGoogle Scholar
• 8  Eckerle LD, Lu X, Sperry SM, Choi L, Denison MR: High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. J. Virol.81(22),12135–12144 (2007).
  Medline CASGoogle Scholar
• 9  Eigen M: Selforganization of matter and the evolution of biological macromolecules. Naturwissenschaften58(10),465–523 (1971).
  Medline CASGoogle Scholar
• 10  Domingo E, Martinez-Salas E, Sobrino F et al.: The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance: a review. Gene.40(1),1–8 (1985).
  Medline CASGoogle Scholar
• 11  Eigen M, Schuster P: The hypercycle. A principle of natural self-organization. Part A: emergence of the hypercycle. Naturwissenschaften64(11),541–565 (1977).
  Medline CASGoogle Scholar
• 12  Holland JJ, Domingo E, de la Torre JC, Steinhauer DA: Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J. Virol.64(8),3960–3962 (1990).
  Medline CASGoogle Scholar
• 13  Loeb LA, Essigmann JM, Kazazi F et al.: Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl Acad. Sci. USA96(4),1492–1497 (1999).
  Medline CASGoogle Scholar
• 14  Loeb LA, Mullins JI: Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs. AIDS Res. Hum. Retroviruses16(1),1–3 (2000).
  Medline CASGoogle Scholar
• 15  Anderson JP, Daifuku R, Loeb LA: Viral error catastrophe by mutagenic nucleosides. Annu. Rev. Microbiol.58,183–205 (2004).
  Medline CASGoogle Scholar
• 16  Holmes EC, Moya A: Is the quasispecies concept relevant to RNA viruses? J. Virol.76(1),460–465 (2002).
  Medline CASGoogle Scholar
• 17  Domingo E: Quasispecies theory in virology. J. Virol.76(1),463–465 (2002).
  Medline CASGoogle Scholar
• 18  Eigen M: Error catastrophe and antiviral strategy. Proc. Natl Acad. Sci. USA99(21),13374–13376 (2002).
  Medline CASGoogle Scholar
• 19  Summers J, Litwin S: Examining the theory of error catastrophe. J. Virol.80(1),20–26 (2006).
  Medline CASGoogle Scholar
• 20  Bull JJ, Sanjuan R, Wilke CO: Theory of lethal mutagenesis for viruses. J. Virol.81(6),2930–2939 (2007).▪▪ Theoretical treatment of lethal mutagenesis.
  Medline CASGoogle Scholar
• 21  Sierra S, Davila M, Lowenstein PR, Domingo E: Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J. Virol.74(18),8316–8323 (2000).
  Medline CASGoogle Scholar
• 22  Grande-Perez A, Lazaro E, Lowenstein P, Domingo E, Manrubia SC: Suppression of viral infectivity through lethal defection. Proc. Natl Acad. Sci. USA102(12),4448–4452 (2005).
  Medline CASGoogle Scholar
• 23  Wilke CO: Quasispecies theory in the context of population genetics. BMC Evol. Biol.5,44 (2005).
  MedlineGoogle Scholar
• 24  Wilke CO, Wang JL, Ofria C, Lenski RE, Adami C: Evolution of digital organisms at high mutation rates leads to survival of the flattest. Nature412(6844),331–333 (2001).▪ Computational demonstration of mutational robustness.
  Medline CASGoogle Scholar
• 25  Schuster P, Swetina J: Stationary mutant distributions and evolutionary optimization. Bull. Math. Biol.50(6),635–660 (1988).
  Medline CASGoogle Scholar
• 26  Comas I, Moya A, Gonzalez-Candelas F: Validating viral quasispecies with digital organisms: a re-examination of the critical mutation rate. BMC Evol. Biol.5(1),5 (2005).
  MedlineGoogle Scholar
• 27  van Nimwegen E, Crutchfield JP, Huynen M: Neutral evolution of mutational robustness. Proc. Natl Acad. Sci. USA96(17),9716–9720 (1999).
  Medline CASGoogle Scholar
• 28  Ratinier M, Boulant S, Combet C et al.: Transcriptional slippage prompts recoding in alternate reading frames in the hepatitis C virus (HCV) core sequence from strain HCV-1. J. Gen. Virol.89(Pt 7),1569–1578 (2008).
  Medline CASGoogle Scholar
• 29  Dinman JD, Ruiz-Echevarria MJ, Peltz SW: Translating old drugs into new treatments: ribosomal frameshifting as a target for antiviral agents. Trends Biotechnol.16(4),190–196 (1998).
  Medline CASGoogle Scholar
• 30  Crotty S, Cameron CE, Andino R: RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl Acad. Sci. USA98(12),6895–6900 (2001).▪▪ Empirical demonstration of lethal mutagenesis of poliovirus using ribavirin.
  Medline CASGoogle Scholar
• 31  Pariente N, Sierra S, Lowenstein PR, Domingo E: Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J. Virol.75(20),9723–9730 (2001).
  Medline CASGoogle Scholar
• 32  Airaksinen A, Pariente N, Menendez-Arias L, Domingo E: Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology311(2),339–349 (2003).
  Medline CASGoogle Scholar
• 33  Domingo E, Escarmis C, Lazaro E, Manrubia SC: Quasispecies dynamics and RNA virus extinction. Virus Res.107(2),129–139 (2005).
  Medline CASGoogle Scholar
• 34  Ruiz-Jarabo CM, Ly C, Domingo E, de la Torre JC: Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology308(1),37–47 (2003).
  Medline CASGoogle Scholar
• 35  Daifuku R: Stealth nucleosides: mode of action and potential use in the treatment of viral diseases. BioDrugs17(3),169–177 (2003).
  Medline CASGoogle Scholar
• 36  Cummings KJ, Lee SM, West ES et al.: Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA285(2),193–199 (2001).
  Medline CASGoogle Scholar
• 37  Davis GL, Esteban-Mur R, Rustgi V et al.: Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med.339(21),1493–1499 (1998).
  Medline CASGoogle Scholar
• 38  Lau JY, Tam RC, Liang TJ, Hong Z: Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology.35(5),1002–1009 (2002).
  Medline CASGoogle Scholar
• 39  Andrei G, De Clercq E: Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res.22(1),45–75 (1993).
  Medline CASGoogle Scholar
• 40  Huggins JW: Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis.11(Suppl. 4),S750–S761 (1989).
  Medline CASGoogle Scholar
• 41  Krilov LR: Respiratory syncytial virus: update on infection, treatment, and prevention. Curr. Infect. Dis. Rep.3(3),242–246 (2001).
  MedlineGoogle Scholar
• 42  ICN Pharmaceuticals ICM. 7.5% Virazole^® cream approved by the health ministry of the Russian federation. California, CA, USA (1998) (News release).
  Google Scholar
• 43  Booth CM, Matukas LM, Tomlinson GA et al.: Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA289(21),2801–2809 (2003).
  Medline CASGoogle Scholar
• 44  Page T, Connor JD: The metabolism of ribavirin in erythrocytes and nucleated cells. Int. J. Biochem.22(4),379–383 (1990).
  Medline CASGoogle Scholar
• 45  Miller JP, Kigwana LJ, Streeter DG et al.: The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann. NY Acad. Sci.284,211–229 (1977).
  Medline CASGoogle Scholar
• 46  Graci JD, Cameron CE: Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol.16(1),37–48 (2006).
  Medline CASGoogle Scholar
• 47  Streeter DG, Witkowski JT, Khare GP et al.: Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl Acad. Sci. USA70(4),1174–1178 (1973).
  Medline CASGoogle Scholar
• 48  Crotty S, Maag D, Arnold JJ et al.: The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med.6(12),1375–1379 (2000).
  Medline CASGoogle Scholar
• 49  Contreras AM, Hiasa Y, He W et al.: Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol.76(17),8505–8517 (2002).
  Medline CASGoogle Scholar
• 50  Maag D, Castro C, Hong Z, Cameron CE: Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem.276(49),46094–46098 (2001).
  Medline CASGoogle Scholar
• 51  Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR: The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology310(2),333–342 (2003).
  Medline CASGoogle Scholar
• 52  Lanford RE, Chavez D, Guerra B et al.: Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol.75(17),8074–8081 (2001).
  Medline CASGoogle Scholar
• 53  Day CW, Smee DF, Julander JG et al.: Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res.67(1),38–45 (2005).
  Medline CASGoogle Scholar
• 54  Severson WE, Schmaljohn CS, Javadian A, Jonsson CB: Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol.77(1),481–488 (2003).
  Medline CASGoogle Scholar
• 55  Chung DH, Sun Y, Parker WB et al.: Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus. J. Virol.81(21),11722–11729 (2007).
  Medline CASGoogle Scholar
• 56  Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky JM: Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J. Virol.9,9 (2007).
  Google Scholar
• 57  Lutchman G, Danehower S, Song BC et al.: Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology132(5),1757–1766 (2007).
  Medline CASGoogle Scholar
• 58  Perelson AS, Layden TJ: Ribavirin: is it a mutagen for hepatitis C virus? Gastroenterology132(5),2050–2052 (2007).
  Medline CASGoogle Scholar
• 59  Hofmann WP, Polta A, Herrmann E et al.: Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology132(3),921–930 (2007).
  Medline CASGoogle Scholar
• 60  Lin CC, Xu C, Zhu N, Yeh LT: Absorption, metabolism, and excretion of [¹⁴C] viramidine in humans. Antimicrob. Agents Chemother.50(7),2368–2373 (2006).
  Medline CASGoogle Scholar
• 61  Wu JZ, Yeh LT, Lin CC, Hong Z: Conversion of viramidine to ribavirin in vivo by adenosine deaminase and its inhibition by 2´-deoxycoformycin. Antivir. Chem. Chemother.17(1),33–39 (2006).
  Medline CASGoogle Scholar
• 62  Fang C, Srivastava P, Lin CC: Effect of ribavirin, levovirin and viramidine on liver toxicological gene expression in rats. J. Appl. Toxicol.23(6),453–459 (2003).
  Medline CASGoogle Scholar
• 63  Moriyama K, Suzuki T, Negishi T et al.: Effects of introduction of hydrophobic group on ribavirin base on mutation induction and anti-RNA viral activity. J. Med Chem.51(1),159–166 (2008).
  Medline CASGoogle Scholar
• 64  Graci JD, Cameron CE: Challenges for the development of ribonucleoside analogues as inducers of error catastrophe. Antivir. Chem. Chemother.15(1),1–13 (2004).
  Medline CASGoogle Scholar
• 65  Traut TW: Physiological concentrations of purines and pyrimidines. Mol. Cell Biochem.140(1),1–22 (1994).
  Medline CASGoogle Scholar
• 66  Martin P, Jensen DM: Ribavirin in the treatment of chronic hepatitis C. J. Gastroenterol. Hepatol.23(6),844–855 (2008).
  Medline CASGoogle Scholar
• 67  Loakes D: Survey and summary: the applications of universal DNA base analogues. Nucleic Acids Res.29(12),2437–2447 (2001).
  Medline CASGoogle Scholar
• 68  Loakes D, Brown DM, Linde S, Hill F: 3-nitropyrrole and 5-nitroindole as universal bases in primers for DNA sequencing and PCR. Nucleic Acids Res.23(13),2361–2366 (1995).
  Medline CASGoogle Scholar
• 69  Harki DA, Graci JD, Korneeva VS et al.: Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-β-D-ribofuranosyl-3-nitropyrrole. Biochemistry41(29),9026–9033 (2002).
  Medline CASGoogle Scholar
• 70  Nichols R, Andrews PC, Zhang P, Bergstrom DE: A universal nucleoside for use at ambiguous sites in DNA primers. Nature369(6480),492–493 (1994).
  Medline CASGoogle Scholar
• 71  Harki DA, Graci JD, Edathil JP et al.: Synthesis of a universal 5-nitroindole ribonucleotide and incorporation into RNA by a viral RNA-dependent RNA polymerase. Chembiochem.8(12),1359–1362 (2007).
  Medline CASGoogle Scholar
• 72  Loakes D, Brown DM: 5-nitroindole as an universal base analogue. Nucleic Acids Res.22(20),4039–4043 (1994).
  Medline CASGoogle Scholar
• 73  Chiaramonte M, Moore CL, Kincaid K, Kuchta RD: Facile polymerization of dNTPs bearing unnatural base analogues by DNA polymerase α and Klenow fragment (DNA polymerase I). Biochemistr.42(35),10472–10481 (2003).
  Medline CASGoogle Scholar
• 74  Zamyatkin DF, Parra F, Alonso JM et al.: Structural insights into mechanisms of catalysis and inhibition in Norwalk virus polymerase. J. Biol. Chem.283(12),7705–7712 (2008).
  Medline CASGoogle Scholar
• 75  Yu H, Eritja R, Bloom LB, Goodman MF: Ionization of bromouracil and fluorouracil stimulates base mispairing frequencies with guanine. J. Biol. Chem.268(21),15935–15943 (1993).
  Medline CASGoogle Scholar
• 76  Suen W, Spiro TG, Sowers LC, Fresco JR: Identification by UV resonance Raman spectroscopy of an imino tautomer of 5-hydroxy-2´-deoxycytidine, a powerful base analog transition mutagen with a much higher unfavored tautomer frequency than that of the natural residue 2´-deoxycytidine. Proc. Natl Acad. Sci. USA96(8),4500–4505 (1999).
  Medline CASGoogle Scholar
• 77  Harki DA, Graci JD, Galarraga JE et al.: Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases. J. Med. Chem.49(21),6166–6169. (2006).
  Medline CASGoogle Scholar
• 78  Harris KS, Brabant W, Styrchak S, Gall A, Daifuku R: KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res.67(1),1–9 (2005).
  Medline CASGoogle Scholar
• 79  Murakami E, Basavapathruni A, Bradley WD, Anderson KS: Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases. Antiviral Res.67(1),10–17 (2005).
  Medline CASGoogle Scholar
• 80  Samuels BL, Herndon JE 2nd, Harmon DC et al.: Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a Phase II study by the Cancer and Leukemia Group B. Cancer82(8),1578–1584 (1998).
  Medline CASGoogle Scholar
• 81  No authors listed. Novel anti-HIV agent enters Phase IIa clinical trial. Expert Rev. Anti Infect. Ther.5(4),540–541 (2007).
  MedlineGoogle Scholar
• 82  Negishi K, Williams DM, Inoue Y et al.: The mechanism of mutation induction by a hydrogen bond ambivalent, bicyclic N4-oxy-2´-deoxycytidine in Escherichia coli. Nucleic Acids Res.25(8),1548–1552 (1997).
  Medline CASGoogle Scholar
• 83  Moriyama K, Otsuka C, Loakes D, Negishi K: Highly efficient random mutagenesis in transcription-reverse-transcription cycles by a hydrogen bond ambivalent nucleoside 5´-triphosphate analogue: potential candidates for a selective anti-retroviral therapy. Nucleosides Nucleotides Nucleic Acids20(8),1473–1483 (2001).
  Medline CASGoogle Scholar
• 84  Graci JD, Harki DA, Korneeva VS et al.: Lethal mutagenesis of poliovirus mediated by a mutagenic pyrimidine analogue. J. Virol.81(20),11256–11266 (2007).
  Medline CASGoogle Scholar
• 85  Brown DM, Lin PK: Synthesis and duplex stability of oligonucleotides containing adenine-guanine analogues. Carbohydr Res.216,129–139 (1991).
  Medline CASGoogle Scholar
• 86  Hill F, Williams DM, Loakes D, Brown DM: Comparative mutagenicities of N6-methoxy-2,6-diaminopurine and N6-methoxyaminopurine 2´-deoxyribonucleosides and their 5´-triphosphates. Nucleic Acids Res.26(5),1144–1149 (1998).
  Medline CASGoogle Scholar
• 87  Too K, Brown DM, Bongard E et al.: Anti-malarial activity of N6-modified purine analogues. Bioorg. Med. Chem.15(16),5551–5562 (2007).
  Medline CASGoogle Scholar
• 88  Graci JD, Too K, Smidansky ED et al.: Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues. Antimicrob. Agents Chemother.52(3),971–979 (2008).
  Medline CASGoogle Scholar
• 89  Nordlund P, Reichard P: Ribonucleotide reductases. Annu. Rev. Biochem.75,681–706 (2006).
  Medline CASGoogle Scholar
• 90  Carroll SS, Tomassini JE, Bosserman M et al.: Inhibition of hepatitis C virus RNA replication by 2´-modified nucleoside analogs. J. Biol. Chem.278(14),11979–11984 (2003).
  Medline CASGoogle Scholar
• 91  Migliaccio G, Tomassini JE, Carroll SS et al.: Characterization of resistance to non-obligate chain terminating ribonucleoside analogs which inhibit HCV replication in vitro. J. Biol. Chem.278(49),49164–49170 (2003).
  Medline CASGoogle Scholar
• 92  Sanjuan R, Cuevas JM, Furio V, Holmes EC, Moya A: Selection for robustness in mutagenized RNA viruses. PLoS Genet.3(6),e93 (2007).
  MedlineGoogle Scholar
• 88  Codoner FM, Daros JA, Sole RV, Elena SF: The fittest versus the flattest: experimental confirmation of the quasispecies effect with subviral pathogens. PLoS Pathog.2(12),e136 (2006).
  MedlineGoogle Scholar
• 94  Martin V, Grande-Perez A, Domingo E: No evidence of selection for mutational robustness during lethal mutagenesis of lymphocytic choriomeningitis virus. Virology378(1),185–192 (2008).
  Medline CASGoogle Scholar
• 95  Pfeiffer JK, Kirkegaard K: A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl Acad. Sci. USA100(12),7289–7294 (2003).▪▪ Along with [96], identifies a ribavirin-resistant poliovirus and provides characterization of the high-fidelity polymerase that confers resistance.
  Medline CASGoogle Scholar
• 96  Arnold JJ, Vignuzzi M, Stone JK, Andino R, Cameron CE: Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J. Biol. Chem.280(27),25706–25716 (2005).▪▪ Along with [95], identifies a ribavirin-resistant poliovirus and provides characterization of the high-fidelity polymerase that confers resistance.
  Medline CASGoogle Scholar
• 97  Sierra M, Airaksinen A, Gonzalez-Lopez C et al.: Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J. Virol.81(4),2012–2024 (2007).▪ Identification of a foot-and-mouth disease virus variant with reduced ribavirin incorporation efficiency.
  Medline CASGoogle Scholar
• 98  Korneeva VS, Cameron CE: Structure-function relationships of the viral RNA-dependent RNA polymerase: fidelity, replication speed, and initiation mechanism determined by a residue in the ribose-binding pocket. J. Biol. Chem.282(22),16135–16145 (2007).
  Medline CASGoogle Scholar
• 99  Graci JD, Cameron CE: Lethal mutagenesis: exploiting error-prone replication of riboviruses for antiviral therapy. In: Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats. Torrence PF (Ed.). Wiley-Interscience, Hoboken, NJ, USA 203–220 (2005).
  Google Scholar
• 100  Holmes EC: Patterns of intra- and interhost nonsynonymous variation reveal strong purifying selection in dengue virus. J. Virol.77(20),11296–11298 (2003).
  Medline CASGoogle Scholar
• 101  Woelk CH, Holmes EC: Reduced positive selection in vector-borne RNA viruses. Mol. Biol. Evol.19(12),2333–2336 (2002).
  Medline CASGoogle Scholar
• 201  US FDA. www.fda.gov/oashi/aids/virals.html
  Google Scholar
• 202  KORONIS. KP-1461 for HIV. www.koronispharma.com/KP1461forHIV.html
  Google Scholar